Figure 3.
Forest plot for the acute VTE treatment study of the Mantel-Haenszel–weighted rate difference for composite primary efficacy end point (complete VTE resolution, freedom from recurrent VTE, and freedom from VTE-related death) by subgroup. DE, dabigatran etexilate.

Forest plot for the acute VTE treatment study of the Mantel-Haenszel–weighted rate difference for composite primary efficacy end point (complete VTE resolution, freedom from recurrent VTE, and freedom from VTE-related death) by subgroup. DE, dabigatran etexilate.

Close Modal

or Create an Account

Close Modal
Close Modal